Table 2 Completed Sintilimab-based Clinical Trials
From: Recent updates on Sintilimab in solid tumor immunotherapy
Identifier | Tumor | Line | Drug | Phase | Number | ORR(%) | DCR(%) | PFS (m) | OS (m) |
|---|---|---|---|---|---|---|---|---|---|
NCT03114683 (ORIENT-1) [6] | Classical Hodgkin’s Lymphoma | ≥ 2nd Lines | IBI308 | II | 96 | 80.4 | 97.8 | NR | NR |
NCT02937116 [25] | gastric/gastroesophageal junction adenocarcinoma | First Line | IBI308 + Capecitabine + oxaliplatin | Ib | 20 | 85 | 100 | 7.5 | NR |
NCT02937116 [16] | non-squamous NSCLC | First Line | IBI308&PC | Ib | 21 | 68.4 | 84.3 | 12.6 | 18.9 |
squamous NSCLC | First Line | IBI308&GC | Ib | 20 | 64.7 | 100 | 6.5 | 15.4 | |
NCT03607539 (ORIENT 11) [14] | non-squamous NSCLC | First Line | IBI308 + Pemetrexed+ Platinum | III | 378 | 51.9 VS 29.8 | 86.8 VS 75.6 | 8.9 VS 5.0 | NR |
NCT03629925 (ORIENT 12) [15] | squamous NSCLC | First-Line | IBI308 + GP | III | 357 | – | – | 5.9 | NR |
NCT03628521 [13] | Advanced NSCLC | First-Line | IBI308 + anlotinib | I | 22 | 77.3 | 100 | NR | NR |
ChiCTR-OIC-17013726 [12] | Resectable NSCLC (stage IA-IIIB) | Neoadjuvant | IBI308 | Ib | 30 | 20 | 90 | NR | NR |
ChiCTR1900023015 [29] | recurrent /metastatic advanced cervical cancer | ≥ 2nd Lines | IBI308 + anlotinib | II | 16 | 54.5 | 100 | NR | NR |
NCT03794440 (ORIENT-32) [24] | advanced HCC | First-line | IBI308+ IBI305 | II | 24 | 25 | 83.3 | 8.4 | NR |